Daily CSR https://www.dailycsr.com/ 2026-05-28T08:11:19+02:00 Webzine Maker https://www.dailycsr.com/favicon.ico Arcera–Fosun Pharma MoU to Boost Global Life Sciences & Neuroscience Innovation 2026-04-28T13:47:00+02:00 https://www.dailycsr.com/Arcera-Fosun-Pharma-MoU-to-Boost-Global-Life-Sciences-Neuroscience-Innovation_a5750.html https://www.dailycsr.com/photo/art/imagette/96294181-67163986.jpg 2026-04-28T13:44:00+02:00 Debashish Mukherjee Arcera–Fosun Pharma MoU to Boost Global Life Sciences & Neuroscience Innovation
Arcera Life Sciences a global life sciences firm based in Abu Dhabi, and Shanghai Fosun Pharmaceutical Group Co Ltd, an innovation-led international pharmaceutical and healthcare company, have announced the signing of a Memorandum of Understanding (MoU). This agreement establishes a long-term strategic partnership focused on licensing, advancing technologies, driving neuroscience innovation, and creating value across the global life sciences landscape.

Aligned with the broader Comprehensive Strategic Partnership between China and the UAE, as well as Abu Dhabi’s Healthcare Life Sciences Vision 2030, the MoU aims to unlock new avenues for innovation and market access in both regions. By combining Fosun Pharma’s strong research, development, and manufacturing expertise with Arcera’s global commercial reach and market access capabilities, the partnership positions Abu Dhabi as a key gateway connecting Chinese biotech innovation with international markets. It also seeks to accelerate patient access to cutting-edge treatments across the Middle East and beyond.

Under the agreement, the two companies will explore collaboration in three primary areas:
  • Licensing opportunities at regional and global levels: Initial efforts will focus on identifying licensing prospects for Fosun Pharma’s portfolio, particularly in oncology, neuroscience, rare diseases, and cardiometabolic conditions. This includes therapies already in late-stage clinical development or commercialized in China.
  • Development of advanced technologies: The partners will assess opportunities to establish joint ventures or new entities aimed at localizing advanced biotechnology in the UAE. This includes capabilities in small molecules, biologics, radiopharmaceuticals, small interfering RNA (siRNA) therapies, as well as cell and gene therapies.
  • Neuroscience collaboration: A key focus will be on neurodegenerative disorders, including Alzheimer’s disease, addressing a major global health need where both innovation and access remain limited.
Isabel Afonso, CEO of Arcera, noted that the agreement represents a significant milestone in building a globally connected life sciences ecosystem anchored in the UAE. She emphasized that combining Fosun Pharma’s drug development expertise with Arcera’s commercial and manufacturing strengths creates a powerful model for accelerating innovation and improving patient access. She also highlighted that this partnership marks Arcera’s first major step in positioning Abu Dhabi as a link between Asian innovation and global markets.

Xingli Wang, Co-President of Fosun Pharma and CEO of its Innovative Medicines Division, described the partnership as an important step in expanding the company’s global footprint and strengthening international collaboration. He expressed confidence that Fosun Pharma’s decades of experience in R&D and manufacturing would support the partnership’s success and stated that both organizations aim to work closely together to bring innovative therapies to patients across the Middle East and worldwide.

]]> Viva Biotech Expands Integrated Drug Discovery and Innovation in Europe 2026-04-07T12:23:00+02:00 https://www.dailycsr.com/Viva-Biotech-Expands-Integrated-Drug-Discovery-and-Innovation-in-Europe_a5683.html https://www.dailycsr.com/photo/art/imagette/95892168-66930591.jpg 2026-04-07T12:22:00+02:00 Debashish Mukherjee Viva Biotech Expands Integrated Drug Discovery and Innovation in Europe
Marking more than 15 years of partnership with Europe’s drug discovery community, Viva Biotech is reinforcing its dedication to the region through operational consistency, steady growth, and scalable collaboration. As the European biopharmaceutical sector undergoes major structural transformation, the importance of a dependable, long-term research partner has become increasingly critical to sustaining progress in key innovation initiatives.

Ensuring Stability in a Shifting Environment
Across Europe, clients see Viva Biotech as more than a service provider—they regard it as a trusted partner and an extension of their own teams. With a strong UK presence and specialized regional teams, the company delivers responsive, well-coordinated support throughout the complexities of the drug discovery process.
  • Consistent Foundation: Despite broader industry disruption, Viva Biotech has maintained stability, growing alongside its European partners for over 15 years.
  • Local Expertise with Global Reach: Its UK base, combined with dedicated business development and project management teams, ensures hands-on support while seamlessly integrating global capabilities across cross-border projects.
  • Trust-Driven Partnerships: In an industry where continuity is crucial, the company focuses on building long-term relationships through reliable delivery of scientific milestones year after year.
Driving Innovation Through Expanded Integrated Capabilities
To support partners in moving from early discovery to candidate selection with greater confidence, Viva Biotech continues to expand its platforms—positioning itself as a fully integrated partner across discovery, development, and manufacturing.
  • Comprehensive Scientific Integration: By combining Structure-Based Drug Discovery (SBDD), cryo-EM, and medicinal chemistry into a unified workflow, the company enables seamless progression from early discovery to lead optimization and candidate selection. Its expertise spans both traditional small molecules and emerging modalities such as peptides and proximity-inducing compounds.
  • AI-Enhanced Discovery: Advanced AI-driven design tools are embedded within workflows, already contributing to nearly 200 projects by enabling faster, data-informed decision-making.
  • Deep Structural Expertise: With experience covering more than 98,000 protein structures, over 200 cryo-EM structures, and 200+ membrane protein targets, partners benefit from strong technical insight.
  • End-to-End Development Support: Extending into CMC and CDMO services, the platform bridges discovery and manufacturing, supporting projects through commercialization and process performance qualification. To date, this integrated model has advanced 295 drug programs at the CMC stage.
Shaping the Future of European Drug Discovery
The past 15 years in Europe have been marked by scientific excellence and strong, trust-based collaborations. Viva Biotech looks forward to continuing this journey, partnering with the next generation of innovators to drive future breakthroughs in drug discovery.

]]>